Hansoh Pharmaceutical Group Company Limited (HK:3692)
:3692
Want to see HK:3692 full AI Analyst Report?
Top Page
Hansoh Pharmaceutical Group Company Limited
(3692)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$41.00
â–²(3.12% Upside)
Action:Reiterated
Date:05/02/26
The score is primarily driven by strong financial performance (high profitability, very low leverage, and solid 2025 cash generation). Offsetting this are mixed/weak technical signals and a relatively expensive valuation (high P/E with low yield).
Positive Factors
High Profitability
Exceptionally high gross and net margins indicate strong pricing power and efficient manufacturing for branded drugs. Durable profitability supports sustained R&D and commercialization spending, underpins healthy ROE, and provides resilience to cyclical downturns in the medium term.
Negative Factors
Margin Variability
Year-to-year swings in operating margins suggest recurring risks from product mix, pricing pressure, or cost timing. Such variability makes long-term earnings less predictable, complicates budgeting for R&D and commercialization, and can amplify performance risk during policy shifts.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Exceptionally high gross and net margins indicate strong pricing power and efficient manufacturing for branded drugs. Durable profitability supports sustained R&D and commercialization spending, underpins healthy ROE, and provides resilience to cyclical downturns in the medium term.
Read all positive factors
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$203.76B
Dividend Yield0.97%
Average Volume (3M)9.67M
Price to Earnings (P/E)34.9
Beta (1Y)0.54
Revenue Growth22.62%
EPS Growth26.23%
CountryHK
Employees8,989
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.93
Shares Outstanding6,064,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.44Price Target Upside16.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.99
Revenue Forecast (FY)HK$16.93B
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Company Description
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic are...
How the Company Makes Money
Hansoh primarily makes money by selling proprietary/branded prescription drugs. Revenue is generated when the company manufactures finished pharmaceutical products (and in some cases active pharmaceutical ingredients) and sells them to hospitals, ...
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
86
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.03B | 12.26B | 10.10B | 9.38B | 9.94B |
| Gross Profit | 13.51B | 11.16B | 9.07B | 8.51B | 9.06B |
| EBITDA | 5.77B | 4.28B | 4.20B | 2.93B | 3.08B |
| Net Income | 5.56B | 4.37B | 3.28B | 2.58B | 2.71B |
Balance Sheet | |||||
| Total Assets | 39.92B | 31.66B | 33.04B | 30.00B | 27.16B |
| Cash, Cash Equivalents and Short-Term Investments | 31.58B | 23.39B | 24.86B | 21.63B | 18.94B |
| Total Debt | 105.14M | 117.89M | 4.30B | 4.38B | 3.83B |
| Total Liabilities | 4.54B | 2.98B | 7.24B | 7.35B | 7.13B |
| Stockholders Equity | 35.38B | 28.68B | 25.79B | 22.65B | 20.03B |
Cash Flow | |||||
| Free Cash Flow | 6.25B | 3.64B | 2.90B | 2.47B | 2.12B |
| Operating Cash Flow | 6.74B | 3.86B | 3.12B | 2.74B | 2.58B |
| Investing Cash Flow | -7.15B | -1.39B | 1.07B | -5.94B | -2.26B |
| Financing Cash Flow | 1.55B | -6.07B | -753.70M | -818.14M | 3.42B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Negative
39.76
Price Trends
35.87
Negative
36.90
Negative
37.05
Negative
Market Momentum
-0.74
Positive
32.29
Neutral
10.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3692, the sentiment is Negative. The current price of 39.76 is above the 20-day moving average (MA) of 36.74, above the 50-day MA of 35.87, and above the 200-day MA of 37.05, indicating a bearish trend. The MACD of -0.74 indicates Positive momentum. The RSI at 32.29 is Neutral, neither overbought nor oversold. The STOCH value of 10.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3692.
Hansoh Pharmaceutical Group Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$203.76B | 34.88 | 16.59% | 0.97% | 22.62% | 26.23% | |
72 Outperform | HK$29.40B | 9.36 | 13.95% | 4.09% | 1.48% | -1.55% | |
58 Neutral | HK$68.27B | 13.21 | 7.19% | 1.69% | 1.52% | 22.54% | |
58 Neutral | HK$30.16B | 6.21 | 7.98% | 2.95% | 4.66% | 20.76% | |
57 Neutral | HK$19.81B | 22.15 | 7.26% | 3.13% | 5.48% | -49.67% | |
56 Neutral | HK$38.86B | 3.39 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3692
Hansoh Pharmaceutical Group Company Limited
33.60
8.58
34.29%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.07
-0.66
-3.93%
HK:1513
Livzon Pharmaceutical Group
27.66
1.46
5.56%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.66
3.46
24.35%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.80
-0.18
-3.67%
HK:0512
Grand Pharmaceutical Group Limited
5.58
-2.87
-33.96%
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh Pharmaceutical Expands RSU Share Pool With Market Purchases
Apr 30, 2026
Hansoh Pharmaceutical has disclosed that the trustee of its post-IPO restricted share unit scheme purchased 370,000 shares on the open market between April 14 and April 22, 2026, at an average price of about HK$39.11 per share, for a total conside...
Hansoh Hands KiOmed Osteoarthritis Licence to Hengrui in Strategic Refocus
Apr 29, 2026
Hansoh Pharmaceutical Group has transferred its exclusive Greater China licence for KiOmed Pharma’s osteoarthritis treatment KiOmedine vs One to Jiangsu Hengrui Pharmaceuticals, following a strategic review of its portfolio and resource allo...
Hansoh Pharma Wins China Nod for Trials of New Hypertension Drug HS-10522
Apr 29, 2026
Hansoh Pharmaceutical Group has announced that its self-developed Class 1 innovative drug candidate HS-10522 tablets has received two clinical trial approvals from China’s National Medical Products Administration. The approvals authorize cli...
Hansoh Pharma Wins Breakthrough Therapy Designation in China for Prostate Cancer ADC
Apr 29, 2026
Hansoh Pharmaceutical Group said its self-developed B7-H3-targeted antibody-drug conjugate HS-20093 has been granted Breakthrough-Therapy-Designated Drug status by China’s National Medical Products Administration. The proposed indication is ...
Hansoh Pharmaceutical Sets Final 2025 Dividend at HKD 0.20 Per Share
Apr 28, 2026
Hansoh Pharmaceutical Group has announced a final ordinary cash dividend of HKD 0.20 per share for the financial year ended 31 December 2025. The update mainly confirms the date for shareholders’ approval, which is set for 26 June 2026, alig...
Hansoh Pharma Grants 5 Million RSUs to Staff Under Post-IPO Incentive Scheme
Apr 28, 2026
Hansoh Pharmaceutical has granted 4,992,330 restricted share units under its post-IPO RSU scheme to 804 grantees, including one executive director and 803 employees, at a grant price of HK$7.8592 per share against a market price of HK$37.30. The a...
Hansoh Pharma Overhauls Equity Incentives With New 2026 Share Scheme
Apr 28, 2026
Hansoh Pharmaceutical Group has moved to overhaul its equity incentive framework by terminating its existing post-IPO restricted share unit scheme, originally adopted in 2019 and valid for ten years, ahead of schedule. Awards already granted under...
Hansoh Pharma Wins China Breakthrough Therapy Status for Lung Cancer ADC Combo
Apr 16, 2026
Hansoh Pharmaceutical Group has announced that its self-developed B7-H3-targeted antibody-drug conjugate HS-20093, administered by injection in combination with adebrelimab, has been granted Breakthrough-Therapy-Designated Drug status by ChinaR...
Hansoh Pharma Delivers Double-Digit 2025 Growth as Innovative Drugs Drive Earnings and Pipeline Wins
Mar 29, 2026
Hansoh Pharmaceutical Group reported strong 2025 results, with revenue rising 22.6% to RMB15.03 billion and profit up 27.1% to RMB5.56 billion, driven by a 30.4% surge in innovative and collaborative medicines, which now account for 82.2% of sales...
Hansoh Pharmaceutical Proposes HKD 0.20 Final Dividend for 2025
Mar 29, 2026
Hansoh Pharmaceutical Group Company Limited has proposed a final ordinary cash dividend of HKD 0.20 per share for the financial year ended 31 December 2025, reflecting the board’s decision to return cash to shareholders following its annual ...
Hansoh Wins Third China Indication for XINYUE, Expanding Autoimmune Portfolio
Mar 27, 2026
Hansoh Pharmaceutical Group announced that China’s National Medical Products Administration has approved a third indication for its innovative biologic XINYUE (inebilizumab injection), allowing its use with conventional therapies to treat ad...
Hansoh Pharma Wins NMPA Nod to Begin Trials of New Cancer Drug HS-10587
Mar 22, 2026
Hansoh Pharmaceutical Group has received clinical trial approval from China’s National Medical Products Administration for HS-10587 tablets, a Category 1 innovative drug self-developed by the company. The therapy is intended for investigatio...
Hansoh Pharma Wins NMPA Nod to Begin Trials for New PNH Drug
Mar 22, 2026
Hansoh Pharmaceutical Group has received clinical trial approval from China’s National Medical Products Administration for HS-20152 injection, a Category 1 innovative drug self-developed by the company. The therapy is intended for the treatm...
Hansoh Pharma Sets March 29 Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 18, 2026
Hansoh Pharmaceutical Group Company Limited has scheduled a board meeting for March 29, 2026 to review and approve the audited final results of the company and its subsidiaries for the financial year ended December 31, 2025. The board will also co...
Hansoh Pharma Wins NMPA Review Nod for New Targeted Lung Cancer Therapy
Feb 27, 2026
Hansoh Pharmaceutical said China’s National Medical Products Administration has accepted a New Drug Application for Dalmelitinib Mesylate Tablets, an orally administered, highly selective c-MET tyrosine kinase inhibitor developed in-house. T...
Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib
Feb 19, 2026
Hansoh Pharmaceutical Group announced that its innovative lung cancer drug Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, has received European Union approval as a monotherapy. The authorization covers first-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.